Articles tagged with Chemotherapy
A clinical trial led by the University of Oklahoma Health Stephenson Cancer Center has shown promising results with a new drug combination targeting metastatic colorectal cancer in patients with ATM-deficient tumors. The treatment, combining alnodesertib and irinotecan, showed substantial reductions in cancer size in these patients.
Experts warn that new drugs for advanced breast cancer are unaffordable and may lead to unequal treatment access worldwide. The consensus panel recommended prioritizing most effective treatments and using next-generation sequencing for personalized medicine.
A new study from the University of South Australia found that up to 50% of patients are missing out on vital foot care after chemotherapy, despite irreversible nerve damage being a common side effect. Podiatry services can prevent falls, ulcerations, pain, and improve mobility in cancer survivors with CIPN.
A study of 168 patients with ampullary adenocarcinoma reveals that the pancreatobiliary signature and blood vessel invasion are independent indicators of poor outcomes. Tumor deposits are identified as a crucial context-dependent biomarker, predicting who benefits from adjuvant chemotherapy.
The DEFEND study aims to assess whether virtual exercise sessions can be successfully delivered to patients with cancer receiving chemotherapy. Researchers will evaluate the impact on physical function, fatigue, and disability.
A study by Wake Forest University School of Medicine reveals that a stress response in immune cells contributes to chemotherapy-induced nerve damage. By blocking this pathway, researchers aim to develop new treatments to protect cancer patients from debilitating side effects.
Scientists re-engineered a common chemotherapy drug to make it more soluble and effective, targeting cancer cells while leaving healthy tissues unharmed. The new nanomedicine significantly extended survival in animal models of leukemia, showing promise for improved cancer treatment.
A team of researchers identified a unique protein signature that can predict which patients are likely to resist standard therapies, paving the way for personalized treatments. By blocking a specific transporter system, they made tumors more sensitive to treatment, suggesting a promising new avenue for treating colorectal cancer.
Researchers suggest chemotherapy drugs may be responsible for 'chemo brain' symptoms, citing reduced lymphatic vessel growth and impaired cognitive function. The study highlights the need to consider long-term neurological side effects of cancer treatment on quality of life.
A new strategy uses self-assembling peptide nanotubes to deliver doxorubicin into the nucleus of chemotherapy-resistant cancer cells, preserving antitumor activity. The approach utilizes cyclic peptides to stack and self-assemble into hollow cylindrical structures that facilitate drug delivery.
Research found that inflammatory markers are linked to different aspects of cancer-related fatigue, with some effects persisting after treatment. The study suggests targeting inflammation for developing treatments to alleviate this debilitating symptom.
A topical formulation has been shown to reduce the incidence of hand-foot neuropathy in cancer patients undergoing chemotherapy, improving quality of life. The cream, developed at UMH, acts directly on neurosensory pain receptors, reducing hypersensitivity and tolerance to chemotherapy.
A diet rich in cysteine has been shown to activate immune cells that help regenerate intestinal tissue, potentially offering a new way to heal tissue damage from radiation or chemotherapy treatment. The researchers found that cysteine initiates a chain of events leading to the activation of CD8 T cells, which produce cytokines like IL-...
A large-scale population study found that oxaliplatin benefits only younger stage III patients, with no added survival benefit for those over 70. The study suggests using an age threshold to make evidence-based choices about chemotherapy.
The American Society for Radiation Oncology, American Society of Clinical Oncology, and Society of Surgical Oncology jointly published a guideline outlining when post-mastectomy radiation therapy (PMRT) is appropriate based on new evidence. PMRT reduces cancer recurrence risk in patients with node-positive disease or high-risk features.
Adult fibrosarcoma is a rare and highly aggressive malignancy requiring precise diagnosis and multimodal treatment. The case report emphasizes the need for early detection, complete surgical removal, and tailored postoperative care to improve outcomes in patients with this type of tumor.
Research reveals that chemotherapy impairs molecular and behavioral measures of the primary biological clock found in the brain. In a study on female mice, paclitaxel treatment disrupted circadian rhythm-related gene expression and behavioral adaptations to light challenges.
Researchers at MD Anderson have made significant advancements in treating kidney cancer, including the use of metastasis-directed targeted radiation therapy to delay systemic treatments. Additionally, preliminary data from an ELI-002 vaccine trial showed promise in delaying relapse of KRAS-mutated pancreatic and colorectal cancers.
A Mayo Clinic study shows that a shorter, less intense course of radiation and chemotherapy after minimally invasive surgery significantly reduces treatment-related side effects while maintaining high cure rates. The findings apply to intermediate-risk patients, with slightly better disease control in high-risk patients.
Researchers at Michigan State University have developed a hydrogel that can be applied to the scalp before chemotherapy treatment, helping to restrict blood flow and prevent hair loss. The temperature-responsive gel is designed to be easily washed off once treatment is complete.
Forskolin, a natural compound, significantly improves treatment outcomes for KMT2A-r AML by directly stopping leukaemia cell growth and enhancing chemotherapy effectiveness. Forskolin blocks P-glycoprotein 1, allowing more chemotherapy drugs to enter leukaemia cells, making treatments more potent.
A 36-year-old woman was diagnosed with non-gestational ovarian choriocarcinoma, a rare and aggressive tumor that shares symptoms with pregnancy. She received chemotherapy and showed complete response to treatment.
Cancer cells with abundant circular DNA elements (ecDNA) carrying oncogenes like MYCN are resistant to chemotherapy. Combining standard chemotherapy with a secondary therapy targeting these senescent cells leads to improved outcomes in mouse models of neuroblastoma and medulloblastoma.
A groundbreaking cancer drug, KCL-HO-1i, has shown promise in making chemotherapy-resistant cancers more responsive to therapy by targeting a key defence mechanism used by tumours. In preclinical models, the drug has already demonstrated effectiveness in laboratory tests using mouse models of breast cancer.
Researchers found that Fen1 protein improves cell tolerance to alovudine by counteracting the toxic effect of 53BP1. This discovery promises new cancer treatments and biomarkers for cancerous cells with Fen1 deficiency.
This book presents cutting-edge approaches to combat cancer, including exosomal delivery systems, CRISPR/Cas9 gene editing, and immunotoxin therapy. Natural compounds are also examined for their anticancer potential.
A recent study found that a 5 mg dose of olanzapine taken after chemotherapy significantly reduced nausea and vomiting in breast cancer patients, with fewer side effects compared to the standard 10 mg dose. The low-dose regimen was effective for both immediate and delayed symptoms, making it an attractive alternative for patients.
A study documents elite-level strength training during active breast cancer treatment, showing rare retention of squat strength despite chemotherapy. LaShae Rolle, a competitive powerlifter and breast cancer survivor, completed the first-of-its-kind study, demonstrating the feasibility of high-intensity training when carefully managed.
By reprogramming chromatin to prevent cancer cells from adapting to evade treatment, researchers have doubled chemotherapy effectiveness in animal experiments. This approach restores cellular memory, making existing drugs more effective against cancer.
Researchers have discovered a key role of centrosomes in signaling cells to proliferate despite DNA damage, enabling cancer resistance. The study suggests targeting Polo-like kinase 1 could prevent adaptation to therapy-induced DNA damage and drug resistance.
Chemotherapy-induced pyroptosis in bladder cancer can actually make the disease more resistant to treatment by fueling cancer stem cells. Blocking this inflammatory process with belnacasan may overcome chemoresistance in preclinical models.
A new treatment approach using cyclophosphamide has been found to prevent most graft-versus-host disease in mismatched transplants. The study shows that 80% of patients are alive after a year, similar to outcomes seen in fully matched transplants.
This study identifies pre-neadjuvant carcinoembryonic antigen (CEA) and neutrophil-to-lymphocyte ratio (NLR) as significant predictors of postoperative recurrence-free survival in non-small cell lung cancer (NSCLC) patients after neoadjuvant therapy. Smoking history is also a predictor of recurrence in LUSC patients.
Researchers developed patient-specific Cancer Chips to model esophageal tumor microenvironments, enabling accurate prediction of chemotherapy responses. The approach can rapidly stratify patients into responders and non-responders, paving the way for personalized medicine.
The American Society for Radiation Oncology (ASTRO) has updated its guideline on radiation therapy for high-grade diffuse gliomas, the most common primary brain tumor in adults. The new guideline provides evidence-based recommendations for multidisciplinary treatment and addresses optimal radiation dosing, fractionation, and techniques.
Researchers at MD Anderson have made significant breakthroughs in cancer treatment, including improved outcomes for elderly patients with IDH-mutant AML who are not eligible for intensive chemotherapy. Additionally, new targeted therapies have been approved as frontline treatments, while pre-surgical radiation therapy may offer an alte...
Researchers at the University of Oklahoma investigate the overlap between cognitive decline caused by chemotherapy and aging, discovering decreased blood flow, disrupted blood-brain barriers, and senescent cells. Removing these cells with senolytics can improve cerebral blood flow, cognition, and overall brain health.
A study published in The Lancet Global Health found serious quality defects in a significant number of cancer medications from sub-Saharan Africa. Researchers evaluated 251 samples and discovered that one in six medications contained the incorrect quantity of active pharmaceutical ingredient, posing patient safety risks.
The new NCCN Guidelines Navigator tool offers an interactive platform for accessing evidence-based guidelines, facilitating easier searching and navigation. The initiative aims to improve patient care and outcomes by providing healthcare professionals with up-to-date recommendations.
Researchers at the University of Pennsylvania School of Engineering and Applied Science have turned a deadly fungus into a potent cancer-fighting compound. The new compound, called asperigimycins, has shown promising results against leukemia cells, rivaling FDA-approved drugs.
Researchers have developed a test that can predict chemotherapy resistance in cancer patients, based on chromosomal instability signatures. This test has the potential to personalize treatment and reduce side effects for patients.
A new test developed by CNIO scientists can predict which patients will not respond to common chemotherapy drugs, allowing for targeted treatment and reducing side effects. The test uses biomarkers based on chromosomal instability patterns to identify resistant patients.
Patients with metastatic colorectal cancer treated with biweekly TAS-102 showed similar treatment effectiveness while experiencing reduced toxicity and lower rates of myelosuppression compared to standard dosing. This alternative schedule may be particularly useful for older patients or those with chemotherapy-related toxicities.
The CompassHER2 trial found that neoadjuvant THP led to a pathologic complete response (pCR) rate of 64% in patients with early-stage HER2-positive, ER-negative breast cancer. Lower ER expression levels resulted in higher pCR rates among ER-positive tumors.
A new study found that adding immunotherapy to chemotherapy after surgery for patients with stage 3 (node-positive) colon cancer resulted in a 50% reduction in cancer recurrence and death compared to chemotherapy alone. The treatment combination showed significant benefits for patients with deficient DNA mismatch repair genetic makeup.
Researchers at VCU Massey Comprehensive Cancer Center have identified AEG-1 as the active regulator of inflammation responsible for chemotherapy-induced peripheral neuropathy (CIPN). Eliminating AEG-1 using targeted therapies could provide a critical strategy for managing CIPN in cancer patients.
A $2.4 million grant will fund the development of an optical imaging technology to image nerve endings in cancer patients with chemotherapy-induced peripheral neuropathy. The goal is to identify potential biomarkers for the disease, enabling early detection and prevention.
Researchers at UCSF found that certain gut bacteria can reduce chemotherapy side effects by clearing excess drugs and producing the protective vitamin K2. Patients with more beneficial bacteria had fewer side effects, suggesting that probiotics may help mitigate chemotherapy's impact.
A research team from the University of Copenhagen has developed a biotechnological method to produce Taxol, a widely used cancer drug. The new method involves cloning taxol-producing genes and inserting them into yeast cells, making it more cost-effective and sustainable than traditional chemical synthesis.
A nationwide cohort study found that immune checkpoint inhibitors significantly increase the risk of myocarditis in NSCLC patients, with a 7.4-fold increase in risk compared to non-users. Cardiac monitoring for at least six months following ICI initiation is recommended.
A new clinical trial has shown that a lower dose of radiotherapy can lead to higher levels of complete disappearance of cancer and fewer short-term side effects. The treatment approach, led by Professor David Sebag-Montefiore, aims to reduce the burden on patients and healthcare systems.
DiffInvex identifies evolutionary shifts in driver gene repertoires during tumorigenesis and chemotherapy, pinpointing mutational escape routes that let cancers resist treatment. The framework reveals which genes may ignite resistance to anticancer drugs, suggesting a core circuitry boosting strategy.
A real-world study of 1,752 patients with stage III or IV ovarian cancer found that adding bevacizumab to chemotherapy improved overall survival for those with advanced disease and residual cancer. Benefits were mostly seen in high-risk patients, not the general population.
A new study suggests that multi-strain probiotics can alleviate chemotherapy-related side effects such as fatigue, nausea, and weakness. Probiotics have been shown to improve blood urea nitrogen levels and enable patients to perform daily activities more independently.
A study found that satisfying intimate relationships and general social support can reduce cognitive problems experienced by breast cancer patients undergoing chemotherapy. The research suggests that couples therapy could be a helpful option for partnered patients, while oxytocin levels decreased significantly during treatment.
A highly sensitive bone marrow test has shown to double survival rates for patients with AML mutations in NPM1 and FLT3 genes, allowing for early detection of potential relapse. This trial indicates that regular molecular testing can improve long-term survival rates by restarting treatment earlier.
A predictive model combining tumor marker readings with patients' genetic profiles enhances predictions for patient survival and surgery decision-making. The new tool accurately identifies candidates who would benefit from surgery, suggesting that current tumor marker evaluations are inadequate for these genetic profiles.
Scientists have developed a cutting-edge technology to analyze protein turnover in individual cells, enabling them to identify treatment-resistant cancer cells and understand the impact of specific drugs. This breakthrough could lead to advancements in disease diagnostics and treatment strategies.
Researchers developed an AI platform that tracks cancer biomarkers to personalize treatment dose adjustments for patients with advanced solid tumors. The study resulted in optimal doses being administered to 97.2% of patients, with average reductions of 20%.
Researchers developed DNA origami structures that selectively deliver fluorescent imaging agents to pancreatic cancer cells, enabling more accurate cancer imaging and selective chemotherapy delivery. The study also explored the use of origami-folded DNA molecules loaded with chemotherapy drugs for targeted delivery to cancer cells.